MarketLens
Sign Up

What Does the Alnylam-Inceptive AI Deal Entail

4 months ago
SHARE THIS ON:

What Does the Alnylam-Inceptive AI Deal Entail

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News•3 months ago

GSK, Relation Therapeutics sign up to $110 million AI drug discovery deal

GSK and Relation Therapeutics signed a research collaboration worth up to $110 million, after the British biotech agreed to generate human cellular datasets and train AI models for drug target discove...
Stock News•3 months ago

Big Pharma's $300 Billion Patent Problem Fuels Biotech Deals

Big Pharma is spending at a pace not seen since 2019 to replace ~$300B in drugs losing patent protection, fueling biotech acquisitions.
Stock News•3 months ago

Can Alnylam's Drug Pipeline Fuel Its Long-Term Revenue Growth?

Alnylam's pipeline and partnered programs could expand future revenue sources beyond its growing approved therapy portfolio.

Breaking News

View All →

Top Headlines

View More →
Stock News•59 minutes ago

Jim Cramer sees major implications from SK Hynix's home-run quarter

Stock News•1 hour ago

Google parent Alphabet tumbles after profit disappoints, warns AI is battering its cash flow

Stock News•1 hour ago

Jim Cramer says these tech giants can weather market turbulence

Stock News•1 hour ago

Alphabet Inc. (GOOG) Misses Q3 Earnings and Revenue Estimates

Stock News•1 hour ago

Alphabet (GOOGL) Q3 Earnings and Revenues Miss Estimates